NCT05896527: A reported trial by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05896527 |
|---|---|
| Title | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 2, 2023 |
| Completion date | March 25, 2024 |
| Required reporting date | March 25, 2025, midnight |
| Actual reporting date | March 24, 2025 |
| Date last checked at ClinicalTrials.gov | Nov. 25, 2025 |
| Days late | None |